NCT04099446

Brief Summary

This study seeks to correlate microbial sequencing data from a punch biopsy in patients with skin cancer both melanoma and non-melanoma.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Oct 2019

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 18, 2019

Completed
5 days until next milestone

First Posted

Study publicly available on registry

September 23, 2019

Completed
8 days until next milestone

Study Start

First participant enrolled

October 1, 2019

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2020

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2020

Completed
Last Updated

June 5, 2025

Status Verified

April 1, 2021

Enrollment Period

1 year

First QC Date

September 18, 2019

Last Update Submit

June 2, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Correlation of Skin Microbiome to Cancer via Relative Abundance Found in Microbiome Sequencing

    Relative abundance of bacterial classes within taxonomic phyla and, more broadly, within their domain will be analyzed by sequencing the skin microbiome in both cancerous and non-cancerous areas. These data will then be compared to elucidate unique qualities of the microbiome in skin cancer.

    1 year

Secondary Outcomes (1)

  • Validation of sequencing methods

    1 year

Interventions

There is no intervention for this study

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Adults 18 and older with a diagnosis of skin cancer

You may qualify if:

  • Signed informed consent
  • years of age or older
  • Diagnosis of skin cancer, both melanoma and non-melanoma
  • Able/willing to have a skin punch biopsy in a non-cancerous location

You may not qualify if:

  • Unable/unwilling to sign informed consent
  • Inability to adequately communicate with the investigator or their respective designee and/or comply with the requirements of the entire study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

ProgenaBiome

Ventura, California, 93003, United States

Location

Biospecimen

Retention: SAMPLES WITH DNA

Punch biopsies of skin from both cancerous and non-cancerous areas.

MeSH Terms

Conditions

Skin NeoplasmsMelanomaCarcinoma, Squamous CellCarcinoma, Basal Cell

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsSkin DiseasesSkin and Connective Tissue DiseasesNeuroendocrine TumorsNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasms, Nerve TissueNevi and MelanomasCarcinomaNeoplasms, Glandular and EpithelialNeoplasms, Squamous CellNeoplasms, Basal Cell

Study Officials

  • Sabine Hazan, MD

    ProgenaBiome

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 18, 2019

First Posted

September 23, 2019

Study Start

October 1, 2019

Primary Completion

October 1, 2020

Study Completion

December 1, 2020

Last Updated

June 5, 2025

Record last verified: 2021-04

Data Sharing

IPD Sharing
Will not share

Only aggregated, deidentified data will be made available to other researchers.

Locations